Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker

Kruseová, Jarmila; Hynek, David; Adam, Vojtěch; Kizek, René; Průša, Richard; Hraběta, Jan; Eckschlager, Tomáš

doi:10.3390/ijms140612170

Cited by 5 publications

(4 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The comorbidities had no effect on concentrations of this protein. The result concerts with another trial (36) confi rming no association between the serum MT concentration and infl ammation blood markers in oncologic patients (36).…”

Section: Discussionsupporting

confidence: 53%

“…The results suggested that in the latter group, the therapy applied was more effi cient due to escalated oxidative stress and cell damage. In patients in long-term remission (follow-up ranging from 18 to 39 months), a decrease in MT levels lasted for 2 months after the treatment had been fi nished (36).…”

Section: Discussionmentioning

confidence: 99%

“…Other studies failed to fi nd any association between the blood MT concentrations and tumour characteristics. No relation of MT with the clinical stage or histological grade was found in oropharyngeal SCC (32) and solid paediatric malignancies (36). Moreover, MT blood concentration showed no predictiveness for the response to chemotherapy in prostatic cancer (35).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Serum metallothionein – a potential oncomarker?

Hořáková¹,

Stárek²

2021

BLL

View full text Add to dashboard Cite

INTRODUCTION: Metallothionein's (MT) overexpression has been demonstrated immunohistochemically in neoplastic cells of many tumour types. Its elevation above the physiological level has been confi rmed in circulation of their hosts. The results of studies dealing with the topic have been summarized to verify if this marker can be applied in the current oncologic practise. METHODS: The Pubmed and Google Scholar medical databases were reviewed for full-text articles focused on MT blood (plasma / serum) levels in patients with malignant tumours. RESULTS: In our review, after a precise selection, we included 8 prospective randomized trials encompassing 561 blood samples taken from patients with a large histopathological spectrum of malignancies. In general, signifi cant differences in blood MT levels between oncological patients and healthy subjects were confi rmed. No particular value of the MT level has been demonstrated to be unequivocally predictive of oncologic disease CONCLUSION: The results of our review suggest that although the elevation of MT in blood serum in patients with solid malignancy can be regarded as a promising tumour marker, the recommendations of its applicability in clinical practice require to be derived from further research on extended cohorts of patients

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum metallothionein – a potential oncomarker?

Hořáková¹,

Stárek²

2021

BLL

View full text Add to dashboard Cite

show abstract

“…26 During MT analysis, changes in Cat2 signal (−1.55 V, which represents the current response of the MT complex with components of the Brdicka electrolyte), Co 2+ (−1.25 V) and Cat1 (−1.40 V) corresponding to hydrogen evolution from the supporting electrolyte catalyzed by the MT were observed. 35 The presence of the Cat2 peak is closely connected with the quantification of -SH groups occurring in the Brdicka solution, 36 thus corresponding to the MT level. The voltammograms of human and rabbit MT are shown in Fig.…”

Section: Metallothionein Analysis Using the Brdicka Reactionmentioning

confidence: 93%

The application of capillary electrophoresis, mass spectrometry and Brdicka reaction in human and rabbit metallothioneins analysis

et al. 2018

View full text Add to dashboard Cite

Background. Metallothioneins (MTs) constitute a family of evolutionary conserved low molecular weight proteins with small variations in their amino acid sequences. They play a role in the regulation of trace metals metabolism, in the detoxification of heavy metal ions and in mechanisms controlling growth, differentiation and proliferation of cells. Objectives. The aim of this study was to evaluate the human and rabbit MTs purity and characterization using advanced analytical approaches. Due to the common use of MT from rabbit liver as a model protein, the properties of the rabbit and human MTs were compared. Material and methods. Capillary electrophoresis (CE), matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and Brdicka reaction were used for human and rabbit MTs characterization. Results. In chip CE analysis, changes in the range of 5-8 kDa corresponding to the MT monomer, as well as some peaks of 13-14 kDa corresponding to dimers in both species, were observed. Using MALDI-MS, rabbit (MT-2D) and human (MT-1A, MT-1G, MT-1G + Cd and MT-2A) MTs were identified. In the Brdicka reaction analysis, a lower concentration of MTs from both organisms coincided with a decrease in the signal corresponding to MT level (Cat2). However, human MT gave higher Cat2 peak than the same concentration (0.025 mg/mL) of rabbit MT. Conclusions. The applied methods allowed for the characterization of MTs and gave complementary information about MT isoforms. Altered electrochemical activity of human and rabbit MTs, despite the same number of-sulfhydryl (−SH) groups, was observed, which may be due to different availability of MT cysteinyl groups.

show abstract